Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01356602 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
A Phase 3 study of Acute Gouty Arthritis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 397
- Enrollment target
- 20
- Study locations
NCT01356602 is a Phase 3 study of Acute Gouty Arthritis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 397 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT01356602, a Phase 3 study of Acute Gouty Arthritis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 397 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study assessed the safety and efficacy of canakinumab pre-filled syringes in comparison to triamcinolone acetonide 40 mg and canakinumab lyophilizate in patients that have frequent flares of acute gouty arthritis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Triamcinolone Acetonide
- DRUG Canakinumab pre-filled syringe
- DRUG Canakinumab lyophilized powder
Study Locations (20)
California
- Novartis Investigative Site - Buena Park
- Novartis Investigative Site - Fair Oaks
- Novartis Investigative Site - Norwalk
- Novartis Investigative Site - Orangevale
- Novartis Investigative Site - Pasadena
- Novartis Investigative Site - Westlake Village
Florida
- Novartis Investigative Site - Clearwater
- Novartis Investigative Site - Jupiter
- Novartis Investigative Site - Largo
- Novartis Investigative Site - South Miami
Alabama
- Novartis Investigative Site - Anniston
- Novartis Investigative Site - Gulf Shores
- Novartis Investigative Site - Mobile
Arizona
- Novartis Investigative Site - Chandler
- Novartis Investigative Site - Phoenix
- Novartis Investigative Site - Scottsdale
Georgia
- Novartis Investigative Site - Augusta
- Novartis Investigative Site - Decatur
Idaho
- Novartis Investigative Site - Meridian
Kansas
- Novartis Investigative Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 397 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01356602
The ClinicalTrials.gov registry entry for NCT01356602 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 397 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Gouty Arthritis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01356602 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01356602 about?
NCT01356602 is a clinical study titled "Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients". This study assessed the safety and efficacy of canakinumab pre-filled syringes in comparison to triamcinolone acetonide 40 mg and canakinumab lyophilizate in patients that have frequent flares of acute gouty arthritis.
What is the current status of trial NCT01356602?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 397 participants. The study started on 2011-05. Estimated completion is 2012-09.
What conditions does trial NCT01356602 study?
This clinical trial studies the following conditions: Acute Gouty Arthritis.
What interventions are being tested in trial NCT01356602?
The interventions under investigation include: Placebo (DRUG), Triamcinolone Acetonide (DRUG), Canakinumab pre-filled syringe (DRUG), Canakinumab lyophilized powder (DRUG).
Who is sponsoring clinical trial NCT01356602?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01356602 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Gouty Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.